Stoneridge Reports Substantial Q4 Loss, Issues 2026 Guidance, and Appoints New CEO

summarizeSummary

Stoneridge Inc. reported a substantial net loss for Q4 and full-year 2025, driven by asset impairment and tax valuation allowances, but provided optimistic 2026 guidance and long-term targets, alongside announcing a new CEO.

check_boxKey Events

• Significant Q4 and Full-Year 2025 Losses

  The company reported a Q4 2025 net loss of $(76.9) million and a full-year net loss of $(102.8) million, largely impacted by a $16.7 million asset impairment and $44.5 million in tax valuation allowances. Adjusted net loss for Q4 was $(14.7) million.

• Positive 2026 Full-Year Guidance Issued

  Stoneridge projects 2026 revenue between $625 million and $650 million, representing 4.2% growth (excluding Control Devices), and Adjusted EBITDA of $20 million to $25 million, indicating significant margin improvement.

• Strong Long-Term Financial Targets

  The company set 2027 revenue targets of at least $715 million and EBITDA of at least $44 million, with 2030 targets of $850 million to $1 billion in revenue and $80 million to $120 million in EBITDA.

• Natalia Noblet Appointed New CEO

  Natalia Noblet will assume the role of President and Chief Executive Officer, and a member of the Board of Directors, effective April 1, 2026.

auto_awesomeAnalysis

Stoneridge Inc. reported a challenging fourth quarter and full-year 2025, with a significant GAAP net loss primarily due to a $16.7 million asset impairment and $44.5 million in tax valuation allowances. Despite these substantial losses, the company highlighted strong 69% growth in MirrorEye sales and operational improvements in material and quality-related costs. Looking forward, Stoneridge provided optimistic 2026 guidance, projecting revenue growth and a substantial increase in Adjusted EBITDA, with even higher targets for 2027 and 2030, signaling a strategic focus on its high-growth segments post the Control Devices sale. Additionally, the company announced Natalia Noblet's appointment as the new President and CEO, effective April 1, 2026, marking a significant leadership transition. The filing also reiterated the recent amendment to its credit facility, which extends the maturity date and provides covenant relief, a detail previously disclosed on March 11, 2026.